Trials / Not Yet Recruiting
Not Yet RecruitingNCT07346846
A Study of BGM-2121 in Patients With Advanced Solid Tumors
A Phase 1 First-in-human Study of BGM-2121 in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- BioGate Precision Medicine Corp. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGM-2121 | BGM-2121 treatment |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-11-01
- Completion
- 2028-12-01
- First posted
- 2026-01-16
- Last updated
- 2026-03-02
Locations
3 sites across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07346846. Inclusion in this directory is not an endorsement.